EMA publishes guideline to smooth the way to biosimilar MAbs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published its long-awaited guideline on biosimilar medicines containing monoclonal antibodies, describing the non-clinical and clinical tests that will be needed to demonstrate comparability with the reference drug, as well as the particular safety monitoring requirements.